Portal de investigación
[Translated article] Should Hydroxyisohexyl 3-Cyclohexene Carboxaldehyde (Lyral®) Still be Part of the Baseline Series?
Fecha de publicación:
Fecha Ahead of Print:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Hernández Fernández CP
- Borrego L
- Giménez Arnau AM
- Sanz Sánchez T
- Carrascosa Carrillo JM
- Zaragoza Ninet V
- Serra Baldrich E
- Miquel Miquel FJ
- Silvestre Salvador JF
- Córdoba Guijarro S
- Sánchez Gilo A
- Mercader García P
- Navarro Triviño F
- Tous Romero F
- Melé Ninot G
- Ruiz González I
- Gómez de la Fuente E
- Pastor Nieto MA
- Sánchez-Pedreño Guillén P
- Sánchez Pérez J
- Pereyra Rodríguez JJ
- Gatica Ortega ME
- González Pérez R
- García Doval I
- Gallego Descalzo MA
Grupos
Abstract
BACKGROUND AND OBJECTIVES: Hydroxyisohexyl 3-cyclohexene carboxaldehyde (HICC), or Lyral®, is a fragrance marker that is part of the Fragrance Mix II (FM II) and is still patched as an independent allergen within the European and other baseline series despite the European Commission banning its use in cosmetics in 2021. We aimed to study the prevalence of sensitization to the HICC in Spain and its simultaneous positivity with the FM II to determine whether it should be part of the Spanish baseline series. MATERIAL AND METHOD: We analyzed all consecutive patients simultaneously patch-tested with HICC and FM II within the Spanish Contact Dermatitis Registry (REIDAC) from June 1st, 2018 to December 31st, 2023. RESULTS: A total of 96 (0.8%) out of 12,029 patients analyzed yielded positive to HICC and 396 (3.3%) to FM II. In 53% and 64% of the patients, respectively, findings were considered currently relevant. A total of 72 out of 96 (75%) HICC positives would be detected if only FM II was patched. CONCLUSIONS: Prevalence of HICC sensitization in Spain is low and has decreased in recent years. HICC is a prohibited fragrance in cosmetics and FM II detects 3 in 4 sensitized patients. Our results suggest that HICC should remain outside the Spanish baseline series and support its exclusion from the European baseline series.
Copyright © 2025 AEDV. Publicado por Elsevier España, S.L.U. All rights reserved.
Datos de la publicación
- ISSN/ISSNe:
- 0001-7310, 1578-2190
- Tipo:
- Article
- Páginas:
- 1084-1092
- PubMed:
- 41076186
- Factor de Impacto:
- 0,279 SCImago ℠
- Cuartil:
- Q3 SCImago ℠
Actas Dermo-Sifiliograficas ELSEVIER ESPANA
Citas Recibidas en Web of Science: 1
Documentos
Filiaciones
Keywords
- Baseline series; Batería estándar; Contact dermatitis; Dermatitis de contacto; España; Hidroxiisohexil 3-ciclohexeno carboxaldehído; Hydroxyisohexyl 3-cyclohexene carboxaldehyde; Lyral®; Patch tests; Pruebas epicutáneas; Spain
Cita
Hernández CP,Borrego L,Giménez AM,Sanz T,Carrascosa JM,Zaragoza V,Serra E,Miquel FJ,Silvestre JF,Córdoba S,Sánchez A,Mercader P,Navarro F,Tous F,RODRÍGUEZ M,Melé G,Ruiz I,Gómez de la Fuente E,Pastor MA,Sánchez P,Sánchez J,Pereyra JJ,Gatica ME,González R,García I,Gallego MA. [Translated article] Should Hydroxyisohexyl 3-Cyclohexene Carboxaldehyde (Lyral®) Still be Part of the Baseline Series?. Actas Dermo-Sifilogr. 2025. 116. (10):p. 1084-1092. IF:2,900. (2).